Texas is currently home to 5017 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Houston, Dallas, San Antonio and Austin. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Clinical Evaluation of the MicroSTent® PeripherAl Vascular SteNt in Subjects With Arterial Disease Below the Knee (STAND)
NCT03477604
Recruiting
Randomized multicenter clinical trial consisting of two arms; one arm treated with PTA plus the MicroStent® System and one arm treated with PTA alone. Purpose to evaluate the safety and effectiveness of using the MicroStent® Peripheral Vascular Stent System, hereafter referred to as the MicroStent® System, for the treatment of infrapopliteal lesions in subjects with peripheral arterial disease.
Gender:
All
Ages:
21 years and above
Trial Updated:
10/03/2022
Locations: Cardiothoracic and Vascular Surgeons, Austin, Texas
Conditions: Peripheral Arterial Disease
Register for Updates
An Investigator-Initiated Study to Assess the Association of Diabetic Retinopathy Severity Scale (DRSS) With Level of Decreased Corneal Sensitivity
NCT05566717
Recruiting
Evaluate the association between level of decreased corneal sensitivity and diabetic retinopathy severity scale
Gender:
All
Ages:
18 years and above
Trial Updated:
09/30/2022
Locations: Medical Center Ophthalmology Associates, San Antonio, Texas
Conditions: Diabetic Retinopathy, Neurotrophic Keratitis
Register for Updates
Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS®) Real World Outcomes
NCT04725838
Recruiting
The UPGRADE registry will capture long-term, real-world outcomes to understand the effect of Differential Target Multiplexed (DTM®) programming in the Spinal Cord Stimulation (SCS) implanted population on the management of chronic pain, primarily on its use for trunk and/or limb pain. The clinical study is sponsored by Celéri Health and is funded through a financial grant from Medtronic's External Research Program. The registry study will be conducted across approximately 25 centers in the Unite... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/28/2022
Locations: North Texas Orthopedics & Spine Center- Keller/Alliance, Fort Worth, Texas
Conditions: Chronic Pain
Register for Updates
Evaluation of The Comfort of Orthokeratology Lenses Fit Using A New Software
NCT05389072
Recruiting
As new orthokeratology fitting software emerges onto the market, it is of interest to assess their usefulness in guiding eye practitioners with lens fit. The goal of this study is to evaluate the comfort of Paragon orthokeratology lenses when they are fit using the new Procornea software.
Gender:
All
Ages:
Between 6 years and 35 years
Trial Updated:
09/22/2022
Locations: Bellaire Family EyeCare, Bellaire, Texas
Conditions: Myopia
Register for Updates
Home With TablO outcoMEs (HOME) Registry
NCT04526301
Recruiting
Prospective, multicenter, single arm, post-market study to evaluate real world clinical outcomes in ESRD patients receiving in-home dialysis on the Tablo Hemodialysis System.
Gender:
All
Ages:
15 years and above
Trial Updated:
09/22/2022
Locations: USRC Kidney Research, Plano, Texas
Conditions: End Stage Renal Disease
Register for Updates
Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
NCT04134780
Recruiting
This work explores the possibility of using ultrasound imaging and spectroscopy as a way of monitoring cell death, hence, tumour response to treatment. The hypothesis here is that it can be used as a way of monitoring early response to cancer treatment and predicting which patients continue on in their therapy to have a complete pathological response as a primary endpoint and tumour size decrease as a secondary endpoint. If this work is successful it could be used in the future early on in a can... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/21/2022
Locations: MD Anderson, Houston, Texas
Conditions: Breast Cancer
Register for Updates
Rare and Atypical Diabetes Network
NCT05544266
Recruiting
RADIANT is a network of 14 clinical sites and several laboratories dedicated to the study of atypical diabetes. The objective of this study is to define new forms of diabetes and the unique mechanisms underlying these forms of atypical diabetes. The specific aims are to: Identify and enroll individuals and families with undiagnosed rare and atypical forms of diabetes. Determine the etiologic basis of the metabolic disorder among individuals and families with novel forms of rare and atypical di... Read More
Gender:
All
Ages:
All
Trial Updated:
09/14/2022
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
Register for Updates
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
NCT04375813
Recruiting
eRapa (encapsulated rapamycin) will be investigated for secondary prevention in patients with diagnosed non-muscle invasive bladder cancer (NMIBC) through a phase II double-blind randomized controlled trial of long-term (one year) prevention with eRapa versus placebo. The primary hypothesis is that eRapa decreases the risk of cancer relapse for patients with NMIBC. Secondary hypotheses are that eRapa can improve certain immune parameters and improve cognition and physical function without advers... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/14/2022
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Non-muscle Invasive Bladder Cancer
Register for Updates
Study to Reinforce Immunity (STRI) Phase 2 Clinical Trial
NCT05046561
Recruiting
Protocol STRI12 - Study to Reinforce Immunity (STRI) - A Phase 2 Double-Blind, Randomized, Placebo-Controlled Study to Investigate the Safety and Efficacy of STRI Formula in Non-Hospitalized Participants with COVID-19 (the Study)
Gender:
All
Ages:
18 years and above
Trial Updated:
09/08/2022
Locations: Dorisca Research Consulting, Houston, Texas
Conditions: Covid19
Register for Updates
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
NCT04880187
Recruiting
This study will compare the effects of AXA1125, an orally active mixture of amino acids, compared to placebo, on improving fat and inflammation (steatohepatitis) as well as fibrosis in subjects with non alcoholic steatohepatitis (NASH). as well as the safety and tolerability of AXA1125. Subjects will take one of two different doses of AXA1125 or a placebo twice daily, and a liver biopsy will be done at the beginning and end of the 48-week study.
Gender:
All
Ages:
18 years and above
Trial Updated:
09/07/2022
Locations: Texas Clinical Research Institute, Arlington, Texas
Conditions: Non Alcoholic Steatohepatitis (NASH)
Register for Updates
An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection
NCT03988855
Recruiting
This is an open-label study to evaluate the safety, efficacy, and PK of DNV3837 at a dose of 1.5 mg/kg actual body weight(BW)/day administered via IV infusion in subjects with CDI. The study will be conducted in 2 subsequent parts. In Part 1 of the study, 10 subjects of either sex with severe or non-severe CDI will be enrolled to receive DNV3837. In Part 2 of the study, up to 30 subjects with severe or non-severe CDI will be enrolled to receive DNV3837. In both parts of the study, treatment i... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
09/06/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Clostridium Difficile (C. Difficile)
Register for Updates
Study of Relugolix in Men With Metastatic Castration-Sensitive Prostate Cancer or Non-Metastatic or Metastatic Castration-Resistant Prostate Cancer
NCT04666129
Recruiting
This study is being conducted to assess the safety and tolerability of relugolix with other agents approved for use in combination with androgen deprivation therapy (ADT) for a 12-week treatment period and an additional 40-week safety extension period in men with prostate cancer, either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic or metastatic castration-resistant prostate cancer (nmCRPC or mCRPC).
Gender:
Male
Ages:
18 years and above
Trial Updated:
09/02/2022
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Castration-Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer
Register for Updates